# ImmunityBio, Inc. (IBRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $6.42B  
**Price:** $6.98 (-3.72%)

> ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an FDA-approved interleukin-15 superagonist used in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company operates a vertically integrated model, controlling processes from discovery and research through manufacturing and commercialization via its proprietary BioShield platform, which includes cytokine fusion proteins, cell therapies, DNA vaccines, and recombinant BCG to address supply shortages. ImmunityBio maintains a robust clinical pipeline targeting solid and liquid tumors, such as non-small cell lung cancer and glioblastoma, as well as infectious diseases. Founded in 2014 and headquartered in Morrisville, North Carolina, ImmunityBio focuses on patient-centric innovations that augment natural killer cells, T-cells, macrophages, and dendritic cells for durable immune responses.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $113M | $113M | -$256M | -$351M | — |
| 2024 | $15M | $15M | -$344M | -$414M | — |
| 2023 | $622,000 | $622,000 | -$362M | -$583M | — |
| 2022 | $240,000 | $240,000 | -$351M | -$417M | — |
| 2021 | $934,000 | — | -$330M | -$347M | — |
| 2020 | $605,000 | — | -$221M | -$222M | — |
| 2019 | $2M | — | -$156M | -$158M | — |
| 2018 | $47,000 | — | -$98M | -$96M | — |
| 2017 | $45,000 | — | -$99M | -$96M | — |
| 2016 | $44,000 | — | -$125M | -$121M | — |
| 2015 | $236,000 | — | -$239M | -$237M | — |
| 2014 | $641,000 | — | -$6M | -$6M | — |
| 2013 | $600,000 | — | — | -$2M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $502M | $1.00B | -$500M | $88M | — |
| 2024 | $383M | $871M | -$489M | $143M | — |
| 2023 | $504M | $1.09B | -$587M | $265M | — |
| 2022 | $362M | $812M | -$447M | $105M | — |
| 2021 | $469M | $713M | -$242M | $181M | — |
| 2020 | $221M | $340M | -$120M | $35M | — |
| 2019 | $143M | $22M | $121M | $76M | — |
| 2018 | $182M | $36M | $146M | $17M | — |
| 2017 | $250M | $32M | $219M | $24M | — |
| 2016 | $317M | $24M | $293M | $8M | — |
| 2015 | $367M | $11M | $356M | $176M | — |
| 2014 | $61M | $2M | $58M | $59M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$305M | $4M | -$309M |
| 2024 | -$391M | $7M | -$398M |
| 2023 | -$367M | $31M | -$397M |
| 2022 | -$338M | $78M | -$416M |
| 2021 | -$274M | $34M | -$308M |
| 2020 | -$172M | $2M | -$173M |
| 2019 | -$152M | $4M | -$156M |
| 2018 | -$63M | $13M | -$76M |
| 2017 | -$49M | $35M | -$84M |
| 2016 | -$39M | $7M | -$45M |

Source: [CompaniesByCap](https://companiesbycap.com/company/IBRX)